Android app on Google Play

Judge Accepts Amgen's (AMGN) $762M Plea in Civil Liability Case

December 27, 2012 4:22 PM EST Send to a Friend
Amgen's (NASDAQ: AMGN) previously announced ettlement agreement with the U.S. government, 49 states and the District of Columbia was accepted by the judge today.

Previously, Amgen disclosed a $612 payment to resolve its civil liability related to certain promotional practices related to the drugs Aranesp (darbepoetin alfa), EPOGEN (epoetin alfa), NEUPOGEN (Filgrastim), Neulasta (pegfilgrastim), Enbrel (etanercept) and Sensipar (cinacalcet) as alleged in the unsealed qui tam complaints and $150 million to resolve its criminal liability relating to the marketing of Aranesp. The Company also entered into a Corporate Integrity Agreement with the Office of Inspector General of the U.S. Department of Health and Human Services.




You May Also Be Interested In


Related Categories

Corporate News, FDA, Litigation

Add Your Comment